Your browser doesn't support javascript.
loading
Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader.
Teng, Mingxing; Jiang, Jie; Wang, Eric S; Geng, Qixiang; Toenjes, Sean T; Donovan, Katherine A; Mageed, Nada; Yue, Hong; Nowak, Radoslaw P; Wang, Jinhua; Manz, Theresa D; Fischer, Eric S; Cantley, Lewis C; Gray, Nathanael S.
Afiliação
  • Teng M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Jiang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Wang ES; Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Geng Q; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
  • Toenjes ST; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
  • Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Mageed N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Yue H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Manz TD; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Fischer ES; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Cantley LC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Gray NS; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Angew Chem Int Ed Engl ; 62(18): e202302364, 2023 04 24.
Article em En | MEDLINE | ID: mdl-36898968
ABSTRACT
Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) remains a poorly understood lipid kinase with minimal enzymatic activity but potential scaffolding roles in immune modulation and autophagy-dependent catabolism. Achieving potent and selective agents for PIP4K2C while sparing other lipid and non-lipid kinases has been challenging. Here, we report the discovery of the highly potent PIP4K2C binder TMX-4102, which shows exclusive binding selectivity for PIP4K2C. Furthermore, we elaborated the PIP4K2C binder into TMX-4153, a bivalent degrader capable of rapidly and selectively degrading endogenous PIP4K2C. Collectively, our work demonstrates that PIP4K2C is a tractable and degradable target, and that TMX-4102 and TMX-4153 are useful leads to further interrogate the biological roles and therapeutic potential of PIP4K2C.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autofagia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autofagia Idioma: En Ano de publicação: 2023 Tipo de documento: Article